<DOC>
	<DOCNO>NCT00746174</DOCNO>
	<brief_summary>This study include subject abnormal glucose tolerance test . Using crossover design , evaluate insulin sensitivity intracellular lipid content heart , liver skeletal muscle subject therapy Rosiglitazone placebo . We hypothesize Rosiglitazone improve insulin sensitivity association reduce muscle lipid content may arise either increase lipid oxidation enhance storage fat adipose tissue .</brief_summary>
	<brief_title>Insulin Resistance Intramyocellular Lipid Content Glucose Intolerant Subjects Receiving Rosiglitazone</brief_title>
	<detailed_description>This protocol crossover study include subject abnormal glucose tolerance test . Participants treat community-based practice set receive detail instruction diet glucose self-monitoring . The patient randomly assign treatment 4 mg daily Rosiglitazone placebo . They return clinic 4 week monitor change glucose level , HbA1c liver enzymes . The drug dose increase indicated 8 mg daily patient reevaluate every 4 week . The participant admit General Clinical Research Center UT-Southwestern Medical Center end 16 week measure change follow primary endpoint : 1 ) insulin sensitivity , 2 ) lipid content heart , liver , skeletal muscle , 3 ) lipid oxidation . Additional noninvasive HMRS measurement make quantify muscle lipid content respiratory gas exchange use assess lipid oxidation . Following GCRC admission , patient switch alternative therapy 16 additional week study repeat . We expect Rosiglitazone improve insulin sensitivity association reduce muscle lipid content may arise either increase lipid oxidation enhance storage fat adipose tissue .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age 3065 Fasting plasma glucose &lt; 126 mg/dL plasma glucose &gt; 140 mg/dL &lt; 200 mg/dL two hour challenge 75 gm glucose Taking drug know suspected affect intermediary metabolism ( e.g . thyroid supplement , oral glucocorticoid , anabolic steroid androgen , antidepressant , anorexic drug , xanthine derivative , sympathomimetics , betaagonists ) Taking investigational drug within 30 day start study Alcohol consumption 7 drink per week Recreational drug IV drug abuse Acute chronic liver disease ( SGOT &gt; 42 U/L , SGPT &gt; 48 U/L , GGT &gt; 45 U/L ) Chronic renal insufficiency ( serum creatinine &gt; 1.5 mg/dL ) Uncontrolled hypertension ( systolic/diastolic blood pressure &gt; 160/95mmHg ) Anemia ( hematocrit &lt; 35 % ) Congestive heart failure Metallic prostheses preclude use magnetic resonance image Premenopausal woman without definitive measure prevent pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>insulin sensitivity</keyword>
	<keyword>magnetic resonance spectroscopy ( MRS )</keyword>
	<keyword>lipotoxicity</keyword>
	<keyword>lipid oxidation</keyword>
	<keyword>thiazolidinediones</keyword>
	<keyword>intracellular</keyword>
	<keyword>triglyceride</keyword>
	<keyword>content</keyword>
</DOC>